SGLT2 抑制剂减缓慢性病进展:一篇评论
Rebecca Maxson1, Jessica Starr1, Jeanna Sewell2
1Harrison College of Pharmacy, Auburn University, Birmingham, Alabama, USA.
Clinical therapeutics
|November 11, 2023
概括
现在,-葡萄糖共运输体-2 抑制剂在减缓慢性病 (CKD) 进展方面发挥着关键作用. 最近的试验证实了它们的有效性,从而为CKD管理制定了最新的临床指南.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 影响数以百万计的人,历史上治疗方法有限.
- 列宁- ангиотензин- алдостерон系统抑制剂是减缓CKD进展的主要治疗方法.
- 来自心血管试验的新兴数据表明,SGLT2抑制剂对脏有好处.
研究的目的:
- 审查-葡萄糖共同载体-2抑制剂 (SGLT2i) 在减缓CKD进展中的作用.
- 总结主要SGLT2i结局试验的发现.
- 讨论与CKD中SGLT2i相关的临床影响和指导方针的变化.
主要方法:
- 在PubMed (2015-2023) 的文献搜索中使用"-葡萄糖转运体2抑制剂"和"慢性功能不全".
- 包括临床试验,元分析和人类随机对照试验.
- 专注于评估SGLT2抑制剂对CKD的试验.
主要成果:
- 关键的结局试验 (CREDENCE,DAPA-CKD,EMPA-KIDNEY) 表明SGLT2抑制剂具有显著的益处.
- 这些试验评估了canagliflozin,dapagliflozin和empagliflozin在各种CKD人群中.
- 从这些关键研究中分析了初级和二级结局.
结论:
- -葡萄糖共载体-2抑制剂现在是减缓CKD进展的基石疗法.
- 临床实践指南已更新,将SGLT2抑制剂纳入CKD管理中.
- 了解SGLT2抑制剂的临床使用对于治疗CKD患者至关重要.
相关概念视频
01:28Chronic Kidney Disease III: Interprofessional Care
13
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
13
01:25Chronic Kidney Disease I: Introduction
17
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
17
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
18
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
18
01:24Chronic Kidney Disease II: Clinical Manifestations
11
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
11
01:20Acute Kidney Injury V: Interprofessional Care
11
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
11
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438